• Info
  • Insider Ownership

Insider Trading & Ownership of UBS Oncology Impact Fund L.P.

Location
Boston, MA
Summary
The estimated value of insider holdings of UBS Oncology Impact Fund L.P. is at least $95,297,419 dollars as of 05 Jun 2023. UBS Oncology Impact Fund L.P. is the 10%+ Owner of Cullinan Oncology, Inc. and owns shares of Cullinan Therapeutics, Inc. (CGEM) stock worth about $95.3M.
Signature
/s/ Ansbert Gadicke, managing partner of BioImpact LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.
All Insider Reports
All Insider Reports

Notify me when UBS Oncology Impact Fund L.P. files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of UBS Oncology Impact Fund L.P.

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
CGEM Cullinan Oncology, Inc. 10%+ Owner $95,297,419 16 Sep 2021
TCRR TCR2 THERAPEUTICS INC. 10%+ Owner 01 Jun 2023

Insider Transactions Reported by UBS Oncology Impact Fund L.P.:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.